At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. Our leadership in oncology extends more than 25 years and includes a range of therapies that have helped to transform the treatment landscape for previously underserved patient populations, in some cases shifting paradigms and becoming standard of care. We are building on our portfolio of approved medicines for hematologic cancers and solid tumors and advancing a cutting-edge pipeline focused on the power of innate immunity. We aim to introduce new classes of immunotherapies that can lead to deep, durable responses so that more patients can benefit from – and have access to – innovative medicines. | Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. www.takeda.com | Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI), with expertise in immune and inflammatory diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com | Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. | Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. www.takeda.com
SynOligo Biotechnologies
Headquartered in Morrisville, NC, USA, Synoligo Biotechnologies is a Contract Research and Development Organization (CRDO) specialized in manufacturing complex and highly modified oligonucleotide for academic, biotech start-up and large pharmaceutical communities. Synoligo is a leading oligonucleotide manufacturing company providing high quality, cost-effective custom oligonucleotides at varying scales for research, diagnostic, and therapeutic applications.
Syngene International
Syngene International Ltd. is a leading Integrated Innovation Partner and CRDMO, for the global pharmaceutical, biopharma, biotechnology, and life sciences investment sectors. By combining discovery science, development expertise, and scalable manufacturing under one roof, we eliminate handoff delays, anticipate technical challenges, and align strategies to shorten timelines and reduce risk. As an innovation partner, we connect every stage from concept to IND. With expertise across biologics, ADCs, and targeted protein degradation, we deliver speed, scientific depth, and strategic alignment. Our proprietary SynTACs™ platform advances induced proximity-based therapeutics such as PROTACs, while our AI-driven ecosystem—Syn.AI™, SARchitect™, and SynTIPS™—optimizes design, accelerates analysis, and delivers actionable insights. Powered by our SynVent™ integrated discovery engine, we transform early-stage ideas into viable clinical candidates. Through versatile partnering structures and tailored business models, Syngene supports more than 400 global customers—including leading biotech innovators and multinational companies such as BMS, GSK, Zoetis, and Merck KGaA—to accelerate drug pipelines with capital efficiency, scientific rigor, and world-class manufacturing excellence. | . | Syngene International Ltd. is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene’s more than 5000 scientists offer both skills and the capacity to deliver great science, robust data security, and world-class manufacturing at speed to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Baxter, and Bristol-Myers Squibb as well as 2.2 Mn sq. ft of specialist facilities, Syngene works with biotech companies pursuing leading-edge science, such as GSK, Zoetis, and Merck KGaA. | Specialization – Syngene offers end-to-end services for mammalian and microbial systems, covering diverse modalities and therapeutic areas. This primarily includes mAbs, recombinant proteins, bispecific, biosimilars, and ADCs. About us – Syngene, a leading global CRDMO with over 30 years of experience solving complex R&D challenges, delivers integrated drug discovery, development, and manufacturing services across small and large molecules. Its diverse clientele ranges from global multinationals to small and medium-sized start-ups. Syngene helps biopharma companies accelerate large molecule therapies to market through integrated biologics CDMO services, with manufacturing facilities across the U.S. and India. With a GMP capacity of 50 KL in single-use bioreactors, featuring 500-, 2,000-, and 4,000-liter units designed to deliver economies of scale, Syngene offers innovative, flexible, and efficient solutions to its clientele.
Syncromune
Syncromune is a clinical-stage biopharmaceutical company that is developing the SYNC-T platform immunotherapy for advance solid tumor cancers, with initial focus on metastatic castration-resistant prostate cancer mCRPC). SYNC-T is a novel personalized combination immunotherapy that is performed completely in situ. It is designed to synchronize the location of key components necessary to create a systemic anti-tumor response within the lymphatic system: patient-specific tumor antigens, our multi-target drug, and immune cells. Using a dual-function device delivery system, it first uses partial cryolysis of a target tumor to release the patient’s own tumor antigens. Then, through the same device, SV-102, a multi-target immunotherapeutic consisting of four immune modulators is infused into the zone of cryolysis. The volume of the infusion then promotes drainage of the tumor antigens and SV-102 into regional lymph nodes where they synchronize location with immune cells. Co-localizing these three components can then empower the immune system to activate T cells and mount a systemic anti-tumor response against both primary and metastatic lesions. Our lead candidate SYNC-T Therapy SV-102 is currently being evaluated in the LEGION-100, a Phase 2 trial for mCRPC. To learn more visit www.legion100trial.com or www.syncromune.com.
Stiehl Tech LLC
Stiehl Tech LLC is a medical device company that has developed a new peristaltic pump irrigation system for use in surgical sites, traumatic fractures and wounds, and any infected chronic wound. We have increased the pressure to 12 PSI (ave) and flow rate of 1800 ccs/minute. With vector spray 60 degrees, we substantially increase biofilm bacteria removal compared to pulsatile irrigation. The pump becomes a durable item reducing the unit cost compared to standard pulsatile irrigator.
Stemline, A Menarini Group Company
Stemline Therapeutics, Inc. (“Stemline”) a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Our dedicated team of scientists, specialists, researchers, and developers are committed to providing transformational oncology treatments to those who need it, with the ultimate goal of improving the lives of those impacted by cancer.
Standex Scientific
Standex Scientific, a division of Standex International, delivers innovative cold storage solutions through a portfolio of specialized brands serving the medical, pharmaceutical, and scientific markets. Among its leading brands are Corepoint® Scientific and Custom Biogenic Systems, both trusted for their performance and reliability in critical temperature-controlled applications. Corepoint® Scientific offers a broad portfolio of medical and laboratory-grade refrigerators and freezers designed for secure storage of vaccines, medications, reagents, and biological samples. These products are engineered to meet CDC/VFC requirements, making them ideal for use in hospitals, clinics, research labs, and pharmacies. With a focus on performance, compliance, and energy efficiency, Corepoint® Scientific products feature advanced temperature control, microprocessor-based monitoring, and robust cabinet construction to ensure consistent reliability in demanding environments. Custom Biogenic Systems (CBS) is a global leader in cryogenic storage and sample management. Manufactured in the USA, CBS products include liquid nitrogen freezers, autofill LN₂ storage tanks, and inventory control systems designed for the long-term preservation of biological specimens. Trusted by biobanks, fertility clinics, pharmaceutical companies, and research institutions worldwide, CBS is recognized for industry-leading thermal performance, low liquid nitrogen consumption, and innovative features that enhance safety and ease of use in cryogenic settings. As part of Standex Scientific, both brands are backed by a shared commitment to quality, innovation, and service. From ultra-low cryogenic preservation to consistent medical refrigeration, Standex Scientific offers reliable cold storage solutions that drive advancements in science and healthcare.
St. Jude Children’s Research Hospital Graduate School of Biomedical Sciences
St. Jude Children’s Research Hospital is a world-class research institution dedicated to pediatric cancer and other catastrophic childhood diseases. The first and only National Cancer Institute (NCI)-designated Comprehensive Cancer Center devoted solely to children, St. Jude is also a Center of Excellence for Influenza Research and Surveillance (CEIRS), and a World Health Organization Collaborating Center for Influenza and Childhood Cancer. Our 300 faculty members work across the spectrum of basic, translational, clinical, and population science in a highly collaborative multidisciplinary environment that includes a Nobel laureate and members of the National Academy of Science and the National Academy of Medicine. St. Jude is ranked on Fortune Magazine’s “Best Workplaces in Health Care & Biopharma” and Glassdoor’s “Best Places to Work,” and is located in the heart of Memphis, Tennessee, a vibrant and friendly city at the historic American crossroads of music, trade, food, and culture. We are in pursuit of the brightest minds in biomedical sciences, individuals poised to contribute to our research progress. Other than access to top-quality scientists and mentors, as a researcher at St. Jude, you will have: # A Blend of Academic Freedom and Industrial Efficiency: Access to shared resources and facilities led by expert scientists, coupled with cutting-edge technology, accelerates research productivity. # Customized Professional and Career Growth: Experience specifically designed programs to enhance professional growth and career readiness, empowering researchers for success. # A Sense of Community: St. Jude fosters a vibrant employee community that supports a well-balanced life. A dynamic environment fosters connections and camaraderie among researchers from diverse backgrounds. # Competitive Compensation: Embark on your journey with a competitive salary, comprehensive benefits, and generous relocation assistance, reflecting our commitment to recognizing and investing in talent.
SpringWorks Therapeutics
SpringWorks Therapeutics is a commercial-stage biopharmaceutical company dedicated to improving the lives of patients with rare tumors. We scrutinize promising molecules from every angle to unlock their full potential. We forge collaborations with industry and academic innovators to multiply the opportunities for success. And we build our company with exceptional people who press beyond “good enough” to make a profound impact. In a word, we are tenacious.
SomaLogic (an Illumina company)
SomaLogic™, an Illumina company, is the only high-plex proteomics technology on the market that scales with precision. It provides the largest number of protein measurements and the greatest number of orthogonally confirmed protein reagents in the proteomics industry – 11,000 protein measurements simultaneously from sample volumes as low as 55 µl. This gives researchers access to half of the human proteome in just one assay. Over a decade of proof in major cardiometabolic, neurology and oncology studies using the SomaScan Platform, sponsored by leading pharma companies with more than 1,200 publications to date, have driven efforts to significantly accelerate trials.